Stock Performance On Friday, December 30, 2016, Following The Announcement, Innocoll Holdings’ Shares Nosedived 61.02%, Finishing The Day At $0.69.



The symptoms are relieved by rest, as the blood flow is sufficient while one is resting. This condition is characterized by obstruction or narrowing of the large arteries that are far from the heart and the brain. find out here nowMagnetic shoe inserts can soothe the pain and provide comfort to the tired feet. Therefore it is very necessary to have a proper shoe with a proper sole support. Disclaimer: The information provided in this article is solely for educating the reader. Heel pain may be caused due to various conditions, for example, sprained heel. The problem is easily diagnosed with an X-ray. Treatment: Apply an ice pack to the ankle, as soon as possible, and keep the injured leg in a raised position.

In the Refusal to File letter, the FDA indicated among other things, that XARACOLL should be considered and characterized as a drug/device combination, which would require that the Company submit additional information. Innocoll announced that it will request a Type A meeting with the FDA to respond to several issues, which the Company believes to be addressable and seek details on additional information, if any, will be required. Innocoll said it will disclose additional details in the future after discussions with the FDA. “We expect to work with the FDA over the coming weeks in an effort to address the open issues and to define a path forward for a successful re-filing of our application at the earliest point in time,” said Tony Zook, CEO of Innocoll. In May, 2016, the Company had announced that two placebo-controlled Phase 3 pivotal studies evaluating XARACOLL (bupivacaine-collagen bioresorbable implant) each achieved the primary endpoint as a postoperative pain relief treatment immediately following open abdominal hernia repair. XARACOLL showed consistency across both studies in treatment effect for pain reduction and opioid reduction. Second Setback The FDA refusal is a second setback for Innocoll in recent months. On November 03, 2016, Innocoll announced that based on top-line data from its COACT-1 and COACT-2 Phase 3 clinical trials of COGENZIA (gentamicin collagen topical matrix) in patients with moderate to severe diabetic foot infections administered in conjunction with systemic antibiotics and wound therapy, the standard of care look at here now (SOC), did not meet their primary endpoint of clinical cure of infection after 28 days versus either placebo plus SOC or SOC alone. Stock Performance On Friday, December 30, 2016, following the announcement, Innocoll Holdings’ shares nosedived 61.02%, finishing the day at $0.69. A total volume of 7.83 million shares exchanged hands by the close of the trading session, which was significantly higher than its 3 months average volume of 90.40 thousand shares.

For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/blog-coverage-innocoll-received-fda-131500854.html

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>